Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Corporate & Regulatory

What are the main procedural steps in GDPR and Russian Federal Law 152-FZ: bridging requirements in the pharmaceuticals sector?

Elena Pavlova · January 2026 · 3 min read

Pharmaceutical firms in Russia must satisfy both GDPR and 152-FZ requirements. Key procedural steps differ — and gaps create regulatory risk. Make an enquiry.

Pharmaceutical companies operating in Russia under both GDPR and Russian Federal Law No. 152-FZ face a dual compliance framework whose procedural steps overlap in some areas but diverge in ways that regularly create gaps for foreign-headquartered businesses. The bridging requirements are manageable, but the sequencing matters.

Under Russian data protection law, the foundational procedural obligations include: notification of Roskomnadzor (the federal data protection authority) prior to processing personal data, unless an exemption applies; localisation of Russian citizens' personal data on servers physically located in Russia before any cross-border transfer is made; obtaining freely given, specific, and documented consent for processing special categories of data — which in the pharmaceuticals sector typically covers health information and clinical trial data; and maintaining an internal record of processing activities accessible to Roskomnadzor on request. Under GDPR, the equivalent requirements centre on a lawful basis for processing, a Records of Processing Activities document, Data Protection Impact Assessments for high-risk processing (standard in clinical trials), and transfer mechanisms such as Standard Contractual Clauses for data flows out of the EEA.

The bridging challenge for pharmaceutical companies is that the two regimes handle health data and cross-border transfers differently. Russian law requires localisation as a precondition to any transfer; GDPR requires an adequate transfer mechanism as a condition of the transfer itself. A pharmaceutical company that processes patient or trial-participant data in Russia must therefore satisfy the localisation requirement first, before relying on a GDPR-compliant transfer tool for the onward flow to its EU parent or clinical research organisation. Consent standards also differ: Russian law imposes written consent requirements for health data that are more prescriptive than GDPR's flexibility to rely on alternative lawful bases in the clinical research context.

The practical priority for in-house counsel is a documented mapping of data flows specific to Russian operations — identifying where health data originates, where it is stored, and which regulator holds jurisdiction at each step. Our Data Protection practice note on this framework is available at GDPR and Russian Federal Law 152-FZ: bridging requirements and the related legislative update at Legislative amendment affecting GDPR and Russian 152-FZ.

For advice on aligning your pharmaceutical company's data processing operations with both regimes — make an enquiry: info@vetrovpartners.com |

— Elena Pavlova Associate, Vetrov & Partners vetrovpartners.com/pavlova/

Elena Pavlova advises foreign companies on Russian data protection law (Federal Law No. 152-FZ), regulatory compliance, and distribution arrangements. She assists in due diligence for cross-border transactions and supports the firm's corporate and IP practices.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry